<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/1/2022 7:03:24 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: f0bcff50-21e2-4ab3-b236-73c76feacc77 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:miro="http://miromatrix.com/20220301" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:EntityCentralIndexKey" id="Tc_KEFOxkOxCki5e0frlV4Bmg_2_1">0001527096</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:AmendmentFlag" id="Tc_Px40fH14zEi2H7EJsndzcQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20220301.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001527096</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3e9c210f_4434_47e4_b2b9_26b82887c5dd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:DocumentType" id="Narr_-E03Ot5HOU608xCFNMrRqg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_R8uIU4zWnEyvXABO4nNC4A"><b style="font-weight:bold;">March 1, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:EntityRegistrantName" id="Narr_VzGRCTjS60mF0-umeptyVw"><b style="font-weight:bold;">Miromatrix Medical&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">(Exact name of registrant as specified in its charter)</i></p><a id="_e0d7db20_38aa_4a75_83d3_f5492b52b28f"></a><a id="Tc_IyA0J47NnEKUPXgqhxFOEA_2_0"></a><a id="Tc_fvFdTu7gaEiMlsJCm5nWaw_2_1"></a><a id="Tc_bbaPjMu6JUmnTLBpo0FcSQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:37.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:26.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:36.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:37.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_CJUVALDq-UiWDub3udnxwA_1_0"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:middle;width:26.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:EntityFileNumber" id="Tc_fjqnG5ty20Wr33vm0uBlvA_1_1"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">001-40518</b></ix:nonNumeric></p></td><td style="vertical-align:middle;width:36.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:EntityTaxIdentificationNumber" id="Tc_2H7xF4hPvUKW_arcj3Xw6g_1_2"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">27-1285782</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;width:37.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(State of other jurisdiction of incorporation)</i></p></td><td style="vertical-align:middle;width:26.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Commission File Number)</i></p></td><td style="vertical-align:middle;width:36.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(IRS Employer Identification Number)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:EntityAddressAddressLine1" id="Narr__vWCMDW1skyTe3x9AcMXQw"><b style="font-weight:bold;">6455 Flying Cloud Drive, Suite 107</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:EntityAddressCityOrTown" id="Narr_paF2cSH_2kSKWvQqeEcyrQ"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Eden Prairie</b></ix:nonNumeric><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_vP_HLkQA20-11ZyQV1_jqg"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Minnesota</b></ix:nonNumeric><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:EntityAddressPostalZipCode" id="Narr_Q0wk4JoywkCA6KJNb9Oqvw"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">55344</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">(Address of principal executive offices, including zip code)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:CityAreaCode" id="Narr_-v4CO7W2k02v2R7iqbx2jg"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">952</b></ix:nonNumeric><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">) </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:LocalPhoneNumber" id="Narr_I7w_KdYWeE-AeC5HIkL2Zg"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">942-6000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">(Registrant&#8217;s telephone number, including area code)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_Yrtn8ewAb02NM0uWn9rp4A"><span style="font-family:'Segoe UI Emoji';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_q3cg6amGk0yfqKWWvOznNA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_I3e9dy8gV0KD4wKKuksCtA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_GdU9EBm7R0ejWJm6k7HWjw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Securities registered or to be registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_98eb7085_f64c_4544_b9e1_22e40cdcc250"></a><div style="margin-left:-0.25pt;"><a id="Tc_DLkeREQxoUi1qDsi41iDpA_1_0"></a><a id="Tc_-73cyQM2RUScry_Vpu6zOA_1_1"></a><a id="Tc_sYIbUlCL_kC20JunzjIsjg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.05%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:42.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:41.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:16.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Trading symbol</b></p></td><td style="vertical-align:top;width:42.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:41.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:Security12bTitle" id="Tc_duSQayzzdEel6rv8SksK_Q_2_0">Common stock, $0.00001 par value per share</ix:nonNumeric></p></td><td style="vertical-align:middle;width:16.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" name="dei:TradingSymbol" id="Tc_bZSvBPWqHkSPvK03tZJhrg_2_1">MIRO</ix:nonNumeric></p></td><td style="vertical-align:middle;width:42.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_vtXCpFAorUCQK2AHpQbrhg_2_2">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933&#160;(&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Emerging growth company&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_pGdmkzKpj0uHdP0Owgi-yA"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for&#160;complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#160;<ix:nonNumeric contextRef="Duration_3_1_2022_To_3_1_2022_ZiJ9382Ur0ypSjAwgFzTEQ" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_AZhpJ2yWWEWRhxEYBrk5uA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_ecc4ea45_f513_4b0f_8488_ff289a98f0c8"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Item 5.02.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</p></td></tr></table><a id="_Hlk97022254"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, <span style="background:#ffffff;">Miromatrix Medical Inc. (the &#8220;Company&#8221;)</span> announced the appointment of James M. Douglas to serve as the Company&#8217;s Chief Financial Officer, and entered into an employment agreement with Mr. Douglas effective as of the same date. As Chief Financial Officer, Mr. Douglas will lead the Company&#8217;s finance organization and will assume the duties of the Company&#8217;s principal financial officer and principal accounting officer. The employment agreement provides that Mr. Douglas will receive an initial annual base salary of $390,000, subject to periodic review for increases by the Compensation Committee (the &#8220;Committee&#8221;) of the Company&#8217;s Board of Directors. In addition, he is eligible to earn an incentive bonus on the terms and conditions established by the Committee from time to time. His bonus target for 2022 is 40% of his annual base salary, or $156,000, subject to proration based on the portion of the year served. Mr. Douglas is eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, awards under the Company&#8217;s equity compensation plan(s), 401(k) plan, and paid time off and paid holidays. The employment agreement provides that if Mr. Douglas&#8217;s employment is terminated by the Company, the Company is obligated to pay Mr. Douglas his base salary earned through the date of termination and the value of his paid time off accrued and unused through the date of termination. In addition, upon a termination of his employment by the Company for any reason other than for &#8220;cause,&#8221; or termination by Mr. Douglas for &#8220;good reason,&#8221; each term as defined in the employment agreement, Mr. Douglas will be entitled to payments in an amount equal to six months of his then-current annual base salary, less customary deductions, payable in regular installments during the six-month period immediately following the date of termination, and health insurance benefits for the six months following the date of termination. The Company also entered into a customary confidentiality, non-competition, and non-solicitation agreement with Mr. Douglas concurrently with the execution of the employment agreement. In connection with his appointment, Mr. Douglas was granted an option to purchase 180,000 shares of the Company&#8217;s common stock, vesting equally in four annual installments. </p><a id="_Hlk97022271"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The foregoing descriptions of the employment agreement are qualified by reference to the text of the employment agreement attached as Exhibit 10.1, to this Current Report on Form 8-K, which is incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Brian Niebur, who previously served as the Company&#8217;s Chief Financial Officer and performed the duties of the Company&#8217;s principal financial officer and principal accounting officer, will continue to serve as the Company&#8217;s Vice President of Finance.</p><a id="_42e42d16_b142_48c6_890f_1e01210a8546"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;7.01</b></span>Regulation FD Disclosure.</p><a id="_Hlk97022304"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On March 1, 2022, we issued a press release disclosing Mr. Douglas&#8217;s appointment.&#160;The text of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference into this Item 7.01.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_76821f06_4c95_4041_89c5_a2a05346d836"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;9.01</b></span>Financial Statements and Exhibits.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)</p></td><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibits.</p></td></tr><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20220301xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">10.1</span></a></p></td><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20220301xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated March 1, 2022, with James M. Douglas</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20220301xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">99.1</span></a></p></td><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20220301xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated March 1, 2022</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_695fca20_3576_4738_bd49_ca10f93ad510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dated: March 1, 2022</p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Miromatrix Medical&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.94%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Jeff Ross</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.94%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Jeff Ross</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "tmb-20220301x8k.htm", "description": "8-K", "secsgml_size_bytes": 37405}]
{"company-data": {"conformed-name": "Miromatrix Medical Inc.", "cik": "0001527096", "assigned-sic": "2836", "irs-number": "271285782", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-40518", "film-number": "22699661"}, "business-address": {"street1": "10399 WEST 70TH STREET", "city": "EDEN PRAIRIE", "state": "MN", "zip": "55344", "phone": "(612)202-7026"}, "mail-address": {"street1": "10399 WEST 70TH STREET", "city": "EDEN PRAIRIE", "state": "MN", "zip": "55344"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 1, 2022
Miromatrix Medical Inc.
(Exact name of registrant as specified in its charter)
​
​
​
Delaware
001-40518
27-1285782
(State of other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
​
6455 Flying Cloud Drive, Suite 107
Eden Prairie
,
Minnesota
55344
(Address of principal executive offices, including zip code)
(
952
)
942-6000
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered or to be registered pursuant to Section 12(b) of the Act:
​
​
​
Title of each class
Trading symbol
Name of each exchange on which registered
Common stock, $0.00001 par value per share
MIRO
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
​
​
​
​
Emerging growth company
☒
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 1, 2022,
Miromatrix Medical Inc. (the "Company")
announced the appointment of James M. Douglas to serve as the Company's Chief Financial Officer, and entered into an employment agreement with Mr. Douglas effective as of the same date. As Chief Financial Officer, Mr. Douglas will lead the Company's finance organization and will assume the duties of the Company's principal financial officer and principal accounting officer. The employment agreement provides that Mr. Douglas will receive an initial annual base salary of $390,000, subject to periodic review for increases by the Compensation Committee (the "Committee") of the Company's Board of Directors. In addition, he is eligible to earn an incentive bonus on the terms and conditions established by the Committee from time to time. His bonus target for 2022 is 40% of his annual base salary, or $156,000, subject to proration based on the portion of the year served. Mr. Douglas is eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, awards under the Company's equity compensation plan(s), 401(k) plan, and paid time off and paid holidays. The employment agreement provides that if Mr. Douglas's employment is terminated by the Company, the Company is obligated to pay Mr. Douglas his base salary earned through the date of termination and the value of his paid time off accrued and unused through the date of termination. In addition, upon a termination of his employment by the Company for any reason other than for "cause," or termination by Mr. Douglas for "good reason," each term as defined in the employment agreement, Mr. Douglas will be entitled to payments in an amount equal to six months of his then-current annual base salary, less customary deductions, payable in regular installments during the six-month period immediately following the date of termination, and health insurance benefits for the six months following the date of termination. The Company also entered into a customary confidentiality, non-competition, and non-solicitation agreement with Mr. Douglas concurrently with the execution of the employment agreement. In connection with his appointment, Mr. Douglas was granted an option to purchase 180,000 shares of the Company's common stock, vesting equally in four annual installments.
The foregoing descriptions of the employment agreement are qualified by reference to the text of the employment agreement attached as Exhibit 10.1, to this Current Report on Form 8-K, which is incorporated by reference herein.
Brian Niebur, who previously served as the Company's Chief Financial Officer and performed the duties of the Company's principal financial officer and principal accounting officer, will continue to serve as the Company's Vice President of Finance.
Item 7.01
Regulation FD Disclosure.
On March 1, 2022, we issued a press release disclosing Mr. Douglas's appointment. The text of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference into this Item 7.01.
​
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
​
​
10.1
Employment Agreement, dated March 1, 2022, with James M. Douglas
99.1
Press Release, dated March 1, 2022
104
Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)
​
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 1, 2022
Miromatrix Medical Inc.
​
​
​
By:
/s/ Jeff Ross
​
​
Jeff Ross
​
​
Chief Executive Officer
​
​
​